Allen, Carl E <br/><br/>
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.  [electronic resource] 

 -  Blood  09 2018 
 - 1438-1451 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2018-01-828277  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Alemtuzumab--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Child<br/>Child, Preschool<br/>Female<br/>Graft vs Host Disease--prevention & control<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Infant<br/>Lymphohistiocytosis, Hemophagocytic--therapy<br/>Male<br/>Melphalan--therapeutic use<br/>Survival Analysis<br/>Transplantation Conditioning--methods<br/>Treatment Outcome<br/>Vidarabine--analogs & derivatives<br/>Young Adult